mation of CAR-T cell adoptive immunotherapy bioprocessing: Technology opportunities to debottleneck manufacturing
Bure K., Ball A., Biagioni K., Mehta S., Choudhary R., Arshad Z., Pettitt D., Holländer G., Al-Mossawi H., Faulstich F., Reeve B., Smith JP., Brindley D.
Continued clinical efficacy demonstrations of cell-based immunotherapies (iTx) such as chimeric antigen receptor T cell (CAR-T) therapies has made the prospect increasingly likely of an immunotherapy product achieving conditional market authorization in the short term.